← Back to Analyst Consensus 
RAPT Hold
RAPT Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jan 21, 2026 | Barclays | downgrade | Overweight → Equal-Weight | $58 | 53% |
| Jan 21, 2026 | Leerink Partners | downgrade | Outperform → Market Perform | $58 | 51% |
| Jan 20, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | $58 | 54% |
| Jan 20, 2026 | LifeSci Capital | downgrade | Outperform → Market Perform | $0 | 55% |
| Jan 20, 2026 | TD Cowen | downgrade | Buy → Hold | $0 | 54% |
| Jan 20, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | $58 | 44% |
| Jan 20, 2026 | Clear Street | downgrade | Buy → Hold | $58 | 47% |
| Dec 18, 2025 | TD Cowen | initiate | — → Buy | $0 | 54% |
| Nov 12, 2025 | JP Morgan | maintain | Overweight → Overweight | $57 | 55% |
| Nov 7, 2025 | Barclays | maintain | Overweight → Overweight | $56 | 53% |
| Nov 3, 2025 | Wells Fargo | maintain | Overweight → Overweight | $72 | 54% |
| Oct 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $72 | 44% |
| Oct 27, 2025 | Guggenheim | initiate | — → Buy | $70 | 52% |
| Oct 21, 2025 | Wells Fargo | maintain | Overweight → Overweight | $48 | 54% |
| Oct 21, 2025 | Barclays | maintain | Overweight → Overweight | $58 | 53% |
| Oct 21, 2025 | Clear Street | maintain | Buy → Buy | $60 | 47% |
| Oct 20, 2025 | JP Morgan | upgrade | Neutral → Overweight | $55 | 55% |
| Oct 13, 2025 | Barclays | initiate | — → Overweight | $35 | 53% |
| Sep 30, 2025 | Clear Street | maintain | Buy → Buy | $41 | 47% |
| Sep 26, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $37 | 51% |
| Aug 12, 2025 | UBS | maintain | Neutral → Neutral | $9 | 54% |
| Aug 8, 2025 | Wells Fargo | maintain | Overweight → Overweight | $38 | 54% |
| Jul 30, 2025 | JP Morgan | upgrade | Underweight → Neutral | $14 | 55% |
| Jul 22, 2025 | LifeSci Capital | initiate | — → Outperform | $31 | 55% |
| Jul 10, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $27 | 44% |
| May 22, 2025 | UBS | maintain | Neutral → Neutral | $1 | 54% |
| Mar 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Dec 26, 2024 | HC Wainwright & Co. | upgrade | Neutral → Buy | $10 | 44% |
| Nov 25, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Nov 12, 2024 | Wells Fargo | maintain | Overweight → Overweight | $4 | 54% |
| Nov 12, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Nov 11, 2024 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Sep 9, 2024 | UBS | maintain | Neutral → Neutral | $2 | 54% |
| Aug 20, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Jul 23, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 14, 2024 | Wolfe Research | downgrade | Outperform → Peer Perform | $0 | 54% |
| May 10, 2024 | Barclays | downgrade | Overweight → Equal-Weight | $4 | 53% |
| May 10, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Apr 10, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Mar 27, 2024 | JP Morgan | maintain | Neutral → Neutral | $13 | 55% |
| Feb 22, 2024 | UBS | downgrade | Buy → Neutral | $10 | 54% |
| Feb 21, 2024 | Barclays | maintain | Overweight → Overweight | $13 | 53% |
| Feb 21, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $10 | 51% |
| Feb 21, 2024 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Feb 21, 2024 | JP Morgan | downgrade | Overweight → Neutral | $15 | 55% |
| Feb 20, 2024 | Cantor Fitzgerald | downgrade | Overweight → Neutral | $0 | 50% |
| Feb 16, 2024 | Evercore ISI Group | initiate | — → Outperform | $0 | 58% |
| Feb 15, 2024 | Wolfe Research | initiate | — → Outperform | $39 | 54% |
| Nov 30, 2023 | JP Morgan | maintain | Overweight → Overweight | $35 | 55% |
| Nov 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $41 | 44% |
Price Target Trend
Apr 21, 2026 Latest: $58 May 2, 2026
EPS Estimates
+1q $-0.57
Lo: $-0.72 Hi: $-0.43
2 analysts 0q $-1.03
Lo: $-1.30 Hi: $-0.83
3 analysts 0y $-2.83
Lo: $-2.95 Hi: $-2.74
3 analysts +1y $-2.71
Lo: $-3.26 Hi: $-1.77
3 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days